Dominik Plonner
dominik.plonner@hartmann.info
+49 7321 36 1312
Due to a considerable rise in the number of COVID-19 infections since September, HARTMANN’s core segments are facing significant challenges. On the one hand, there is a temporary strong increase in demand for disinfectants and personal protective equipment, which the company is already meeting in the best possible way, i.e. with measures to expand production capacities and secure supply chains. On the other hand, challenges also stem from the postponement of non-urgent surgeries, which results in a decline in business, for example in sterile surgical products and other product groups in Wound Management. These challenges are reflected in the development of the core segments.
"Overall, the challenging market conditions for the other business segments due to the coronavirus pandemic can be compensated for by considerably increased demand for disinfectants and personal protective equipment."
There is a high degree of forecast uncertainty due to the unclear further course of the coronavirus pandemic and its economic consequences. HARTMANN therefore currently expects the following developments:
The HARTMANN GROUP is one of the leading European providers of professional medical and care products and associated services. Every day, healthcare professionals and patients rely on HARTMANN brands in the segments of Incontinence Management (e.g. MoliCare®), Wound Care (e.g. Zetuvit®, Cosmopor®) and Infection Management (e. g. Sterillium®). This is expressed in our brand promise of “Helps. Cares. Protects.” HARTMANN generated sales of EUR 2.3 billion in the 2023 financial year. Founded in 1818, the Company sells its products and solutions in 130 countries around the world. For the future, the HARTMANN GROUP is currently implementing its strategic Transformation Program with its high-performance, customer-oriented and passionate team.
To learn more about the HARTMANN GROUP, visit www.corporate.hartmann.info.